Joseph Matus Fuisz, president of Fuisz Pharma, said: “The technology described in the acquired patent is highly complementary to the anti abuse portfolio that we previously announced. Importantly, the Gruber patent enables us to offer strong, existing patent protection for our partners.
“We thus believe that this acquisition significantly enhances the value of our anti abuse platform and gives us a very strong IP position in the prevention of opiate abuse.
“This acquisition is also complementary to our technology to aid and abet the absorption of all dosage forms including the ability to bring forth a very novel methodology to specifically play a critical role in the opiate agonist/antagonist pas de deux. This methodology is applicable to all dosage forms.”